40 results about "Atypical mycobacterium" patented technology

Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and/or NTM culture conversion to negative during or after the administration period.

The invention belongs to the field of biomedical detection, relates to the technical field of microbe molecule biology detection, in particular to a multiplex polymerase chain reaction (PCR) kit capable of quickly identifying and diagnosing mycobacterium tuberculosis, nontuberculous mycobacteria, mycobacterium bovis and Bacillus Calmette Guerin vaccine simultaneously, and discloses four primer pair sequences designed for specific segments of four differential genes, namely 16S rRNA, IS6110, Rv2652 and Rv3873 of the mycobacterium, and amplification conditions for multiplex PCR. By the invention, a mycobacteria tuberculosis complex sequence can be quickly and accurately amplified in a sputum sample of a tuberculosis patient, and species identification can be carried out; the sensitivity is 50 colony forming units/template, which is far higher than that of an acid-fast staining method, an inspection procedure for the mycobacterium tuberculosis is greatly simplified, and a detection speed is improved; and meanwhile, different mycobacterium strains can be identified through once PCR, and a technical means is provided for clinic quick diagnosis of tuberculosis and molecular epidemiology survey.

Disclosed are a primer set and/or a probe capable of detecting specific nucleotide sequences of MTC and NTM, a kit for the detection of MTC and NTM, comprising the same, and a method for detecting MTC and NTM by duplex real-time PCR using the same. Useful in detecting genes characteristic of MTC and NTM, the primer sets and/or probes, detection kits, and detection methods can be applied as the clinical diagnosis of diseases caused by MTC and NTM, and therefore find applications in the medical fields including hospitals, research institutes, etc.

The invention relates to the technical field of molecular biology and discloses primers, probes, method and kit for detecting a mycobacterium tuberculosis specific gene. Through a Taqman probe real-time fluorescence PCR method, primers and fluorescent labeled probes are designed according to (gyrB) and 16S rDNA nucleic acid conserved regions. An enzyme and a sample nucleic acid are added into a PCR detection mixed solution of the primers and probes, a FAM channel of a fluorescence PCR device is used for amplification and a desired gene is detected through change of a fluorescence signal. The primers, probes, method and kit have the characteristics of high accuracy, strong specificity and high sensitivity and can realize fast and accurate detection of mycobacterium tuberculosis (MTB) and non-tuberculous mycobacteria (NTM).

The invention relates to a mycobacterium culture medium, a preparation method and a method for culture, identification and drug sensitivity test. The culture medium contains buffer solution, glycerol, trace element, albumin, glucose, antibiotic and a colour-changing agent and the like. The first fourteenth components are added in distilled water, pH is adjusted, high-pressure sterilization is carried out, methyl thiazolyldiphenyl tetrazolium, albumin-oleic acid-glucose liquid and four types of antibiotics are added and the culture medium is obtained. Specimen after pre-treatment is taken and added into the culture medium for culture, and after the color of ae culture hole is changed, the mycobacterium tuberculosis or nontuberculous mycobacteria and drug sensitivity are judged according to the condition of color change of identification holes and drug-sensitivity testing holes. The invention can obtain the results of mycobacterium culture, identification and drug-sensitivity measurement by only one-time inoculated culture, has simple operation, practicability, easy standardization, high positive rate, fastness, strong practicability, low cost, easy promotion and wide application, and is applicable to mycobacterium culture, identification and drug-sensitivity test in the environments of human bodies, animals and sewage and the like.

The invention discloses a medical immunity diagnose technique, especially providing a bacillus tubercle mycobacterium gold mark diagnose agent based on combined protein. Wherein, it uses B cell antigen determinants of bacillus tubercle mycobacterium main excrete proteins as ESAT6, MPT64, PstS-1, Ag85B to combine a new group of protein as antigen, as the specific test antibody in the clinic serology diagnosis of phthisis. The invention combines the B cell antigen determinants of bacillus tubercle mycobacterium main excrete proteins to be displayed by gene project, and purified to attain one new protein, and via gold mark filter method to test the serum of tuberculosis patient. The invention has high sensitivity, simple operation, and high speed, which can identify the sensitized condition caused by contacting the non- bacillus tubercle mycobacterium or inoculating beg vaccine, and the real bacillus tubercle mycobacterium. It can be used in the clinic serology diagnosis of clinic tuberculosis.

The invention discloses application of a rifamycin-quinazine ketone coupling molecule or a three-dimensional isomer thereof or hydrate thereof or a deuterated material thereof, ester thereof, a solvent compound thereof, a crystal form thereof, a metabolic product thereof or pharmaceutically acceptable salt thereof or a pro-drug thereof in resisting nontuberculous mycobacteria. The rifamycin-quinazine ketone coupling molecule has a structure as shown in formula I. The rifamycin-quinazine ketone coupling molecule disclosed by the inention or the three-dimensional isomer thereof or hydrate thereof or the deuterated material thereof, ester thereof, the solvent compound thereof, the crystal form thereof, the metabolic product thereof or the pharmaceutically acceptable salt thereof or the pro-drug thereof can effectively resist nontuberculous mycobacteria, and can be used for treating infection caused by human nontuberculous mycobacteria.

Disclosed are primer sets specific for the IS6110 or 16S rRNA gene characteristic of MTC and for the 16S rRNA gene characteristic of NTM, kits for the detection of MTC and NTM, comprising the same, and methods for detecting MTC and NTM by duplex PCR using the same. Because the primers are exclusive to Mycobacterium tuberculosis and nontuberculous mycobacteria, the methods, which can employ an inexpensive typical PCR cycler, can be a clinical diagnostic means useful for the detection of both Mycobacterium tuberculosis and nontuberculous mycobacteria at the same time, with higher efficiency.

The invention discloses application of besifloxacin or a pharmaceutical composition containing besifloxacin in preparation of a medicine for preventing and/or treating tuberculosis, and relates to the technical field of medicines. Experiments prove that the besifloxacin has a good inhibition effect on mycobacteria and nontuberculous mycobacteria in vitro, can be used for preparing the medicine for resisting the mycobacteria tuberculosis and the medicine for preventing and/or treating tuberculosis, and provides a new medicine choice for treating tuberculosis.